Compounds > lorvotuzumab mertansine
Page last updated: 2024-10-15

lorvotuzumab mertansine

Description

lorvotuzumab mertansine: has antineoplastic activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID139033611
MeSH IDM0582676

Synonyms (2)

Synonym
lorvotuzumab mertansine
Q527070

Research Excerpts

Overview

Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate linking an antimitotic agent (DM1) to an anti-CD56 antibody (lorvotzumab) It is an ADC composed of an anti CD56 humanized N901 monoclonal antibody.

ExcerptReference
"Lorvotuzumab mertansine (IMGN901) is an antibody-drug conjugate linking an antimitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). "( ADVL1522: A phase 2 study of lorvotuzumab mertansine (IMGN901) in children with relapsed or refractory wilms tumor, rhabdomyosarcoma, neuroblastoma, pleuropulmonary blastoma, malignant peripheral nerve sheath tumor, or synovial sarcoma-A Children's Oncolo
Barkauskas, DA; Berg, SL; Cajaiba, M; Cho, SY; Dome, JS; Fox, E; Geller, JI; Hall, D; Kudgus, RA; Pressey, JG; Reid, JM; Smith, MA; Voss, SD; Weigel, BJ, 2020)
"Lorvotuzumab mertansine (LM) is an ADC composed of an anti CD56 humanized N901 monoclonal antibody conjugated via a stable disulfide linker to the maytansinoid DM1. "( Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma.
Berdeja, JG, 2014)
"Lorvotuzumab mertansine (LM) is an antibody-drug conjugate composed of a humanized anti-CD56 antibody, lorvotuzumab, linked via a cleavable disulfide linker to the tubulin-binding maytansinoid DM1. "( Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
Audette, CA; Carrigan, CN; Johnson, HA; LaBelle, A; Lambert, JM; Lutz, RJ; Mayo, MF; Whiteman, KR; Zukerberg, L, )

Toxicity

ExcerptReference
" The adverse event profile was favorable, with a low incidence of grade 3/4 adverse events and no infusion-related reactions."( A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.
Ailawadhi, S; Bojanini, L; Chanan-Khan, A; Gharibo, M; Jagannath, S; Kelly, KR; Kirby, M; Sher, T; Vescio, RA; Wolf, J, 2019)

Dosage Studied

ExcerptReference
" Continued evaluation of optimal dosing levels and schedules will be important to better define the utility of this promising treatment."( Lorvotuzumab mertansine: antibody-drug-conjugate for CD56+ multiple myeloma.
Berdeja, JG, 2014)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's8 (88.89)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (30.00%)5.53%
Reviews4 (40.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (30.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; NSC#: 783609) in Children With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma[NCT02452554]Phase 262 participants (Actual)Interventional2015-10-12Completed
A Phase I, Open-Label, Dose Escalation Study of Weekly Dosing With BB-10901, Followed by a Phase II Efficacy Expansion[NCT00065429]Phase 1/Phase 264 participants (Actual)Interventional2003-04-30Completed
An Open-Label Phase I Study of Bb-10901 (IMGN901, huN901-DM10 in Combination With Lenalidomide and Dexamethasone in Patients With CD56-positive Relapsed or Relapsed/Refractory Multiple Myeloma[NCT00991562]Phase 150 participants (Anticipated)Interventional2009-12-31Completed
A Phase I, Open-Label, Dose Escalation Study of Daily Dosing With BB-10901[NCT00346385]Phase 197 participants (Actual)Interventional2002-03-31Completed
A Phase 1/2 Study to Assess the Safety and Efficacy of Lorvotuzumab Mertansine in Combination With Carboplatin/Etoposide in Patients With Advanced Solid Tumors Including Extensive Stage Small Cell Lung Cancer[NCT01237678]Phase 1/Phase 2181 participants (Actual)Interventional2010-11-30Terminated(stopped due to Study was stopped early due to lack of efficacy signal and safety concerns)
A Phase I Study to Assess The Safety and Pharmacokinetics of BB-10901 (huN901-DM1) Given as an Intravenous Infusion Weekly for Two Consecutive Weeks Every Three Weeks to Subjects With Relapsed and Relapsed Refractory CD56-Positive Multiple Myeloma[NCT00346255]Phase 137 participants (Actual)Interventional2005-04-30Completed
An Open-label Phase II Study of Lorvotuzumab Mertansine (IMGN901) in CD56 Expressing Hematological Malignancies[NCT02420873]Phase 29 participants (Actual)Interventional2015-05-12Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00065429 (2) [back to overview]Phase I Toxicity Based Upon Adverse Events Clasified by the NCI Common Terminology Ctireria Version 2.0 (Phase I)
NCT00065429 (2) [back to overview]Response Evaluation Criteria in Solid Tumors (RESIST) [Phase I and II]
NCT01237678 (7) [back to overview]Maximum Tolerated Dose (MTD) of IMGN901
NCT01237678 (7) [back to overview]Median Overall Survival (OS) in Phase II
NCT01237678 (7) [back to overview]Overall Survival (OS) Rate at 12 Months
NCT01237678 (7) [back to overview]Progression Free Survival (PFS) in Phase II
NCT01237678 (7) [back to overview]Progression Free Survival (PFS) Rate at 6 Months
NCT01237678 (7) [back to overview]Occurrence of Dose Limiting Toxicities (DLT)
NCT01237678 (7) [back to overview]Overview of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
NCT02420873 (1) [back to overview]Overall Response Rate (ORR) of IMGN901 in Participants CD56 Expressing Hematological Malignancies
NCT02452554 (2) [back to overview]Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1
NCT02452554 (2) [back to overview]Incidence of Toxicities of Lorvotuzumab Mertansine, Using the NCI Common Terminology Criteria for Adverse Events Version 4.0

Phase I Toxicity Based Upon Adverse Events Clasified by the NCI Common Terminology Ctireria Version 2.0 (Phase I)

Dose limiting toxicities graded according to common terminology criteria for advers events, version 2.0 and defined as AEs (probably/definitely related to study drug) meeting the NCI CTC criteria, assessed on the basis of the first cycle of therapy (4 weeks of weekly dosing/2 week fu): Hematologic Tox (Grade 4 neutropenia ≥ 5 days, Grade 4 thrombocytopenia, neutropenic infection); Non-Hem Toxicity: (Any grade 3 or 4 non-hematologic toxicity, excluding nausea, vomiting, diarrhea and alopecia); Toxicity present at Screening (concurrent conditions), an increase in severity of 2 or more grades. (NCT00065429)
Timeframe: every 6 weeks

Interventionparticipants (Number)
Non-infective meningitisHyperesthesia Grade 4Peripheral sensory neuropathy Grade 3Fatigue Grade 3Headache Grade 3
Phase I31111

[back to top]

Response Evaluation Criteria in Solid Tumors (RESIST) [Phase I and II]

Response was evaluated by RESIST and Investigator assessment at baseline and every 6 weeks. CR: all target lesions disappear with no clinical or radiographic evidence of disease progression in 2 observations. PR: At least 30% decrease in sum of the longest diameters of target lesions shown in 2 observations. SD: does not qalify for PR or PD based on 2 observations. PD: Either a) the appearance of one or more new lesions, or b) at least a 20% increase in the sum of longest diameters of target lesions (NCT00065429)
Timeframe: 6 weeks

,
Interventionparticipants (Number)
Complete Response (CR) or Partial Response (PR)Stable DiseaseProgressive Disease (PD)Unknown
Phase I010163
Phase II210170

[back to top]

Maximum Tolerated Dose (MTD) of IMGN901

A primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. The MTD was determined based on DLTs that occurred during Cycle 1. (NCT01237678)
Timeframe: 21 days (Cycle 1)

Interventionmg/m^2 (Number)
Phase I - IMGN901 + Carboplatin + Etoposide112

[back to top]

Median Overall Survival (OS) in Phase II

A secondary outcome measure for Phase II was to determine the overall survival of patients treated with IMGN901 in combination with carboplatin/etoposide chemotherapy versus carboplatin/etoposide chemotherapy alone as first-line treatment for patients with extensive stage small cell lung cancer. (NCT01237678)
Timeframe: From the time of enrollment until death on study due to any cause (up to post-treatment follow-up 28 days after last dose, up to 22 months)

Interventionmonths (Median)
Phase II - IMGN901 + Carboplatin + Etoposide10.1
Phase II - Carboplatin + Etoposide10.97

[back to top]

Overall Survival (OS) Rate at 12 Months

OS was analyzed based on a binary definition of the number of patients dead or censored prior to 12 months and the number of patients alive at 12 months. The primary objective of this phase of the study was to compare PFS in the experimental arm (triplet combination) against historical PFS rates. The control arm was primarily planned to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed. Further, the trial was not empowered to permit a statistically informative comparison of the randomized treatment groups with respect to OS and no determination of the OS rate at 12 months for the control arm was performed; therefore only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented. (NCT01237678)
Timeframe: 12 months

Interventionpercentage of participants alive (Number)
Phase II - IMGN901 + Carboplatin + Etoposide61

[back to top]

Progression Free Survival (PFS) in Phase II

The primary outcome measure for Phase II was to determine the efficacy of IMGN901 in combination with carboplatin/etoposide chemotherapy as first-line treatment for patients with extensive stage small cell lung cancer. PFS was defined as the time from enrollment until objective tumor progression according to RECIST 1.1 or death on study due to any cause, whichever occurred first. Only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented as the primary objective of this phase of the study was to compare PFS in the experimental arm (triplet combination) against historical PFS rates for carboplatin and etoposide. The control arm was planned primarily to reliably assess the safety of IMGN901 and to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed. (NCT01237678)
Timeframe: From randomization to objective tumor progression or death (up to post-treatment follow-up 28 days after last dose, up to 22 months)

Interventionmonths (Median)
Phase II - IMGN901 + Carboplatin + Etoposide6.2

[back to top]

Progression Free Survival (PFS) Rate at 6 Months

The trial was not empowered to permit a statistically informative comparison of the randomized treatment groups with respect to PFS. The activity of IMGN901 was assessed by comparing the PFS rate at 6 months in the IMGN901 experimental arm against the historical 6-month PFS rate of 0.44 (equivalently a median PFS = 5 months). Only the results from the experimental arm (IMGN901 + carboplatin + etoposide) are presented as the objective was to compare PFS at 6 months in the experimental arm (triplet combination) against the historical PFS rate of 0.44 (equivalently a median PFS = 5 months) for carboplatin and etoposide. The control arm was planned primarily to reliably assess the safety of IMGN901 and to demonstrate whether the or not the historical assumptions regarding efficacy were confirmed. (NCT01237678)
Timeframe: 6 months

Interventionpercentage of participants (Number)
Phase II - IMGN901 + Carboplatin + Etoposide39

[back to top]

Occurrence of Dose Limiting Toxicities (DLT)

The primary outcome measure for Phase I was to determine the maximum tolerated dose (MTD) and characterize the dose limiting toxicities (DLT) of IMGN901 when administered in combination with carboplatin/etoposide chemotherapy followed by IMGN901 alone in patients with solid tumors. For the purposes of dose escalation and determination of MTD, DLTs were defined as AEs or abnormal laboratory values related to study treatment which occurred in Cycle 1 of the Dose Escalation phase, including any AEs that resulted in failure to meet the criteria for re-treatment. The following events were considered DLTs (using the most current version of CTCAE): febrile neutropenia; Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with bleeding; ≥ Grade 3 peripheral neuropathy; ≥ Grade 3 vomiting, nausea, or diarrhea that persisted despite the use of optimal therapy; other ≥ grade 3 non-hematologic toxicity (with the exception of brief fatigue i.e. ≤ 72 hours and alopecia) (NCT01237678)
Timeframe: 21 days (Cycle 1)

,,,,
Interventionparticipants (Number)
Grade 3 febrile neutropeniaGrade 4 febrile neutropeniaGrade 4 thrombocytopeniaGrade 4 granulocytopeniaGrade 3 lobar pneumonia
IMGN901 112 mg/m2 + Carboplatin AUC 5 + Etoposide 100 mg/m200101
IMGN901 60 mg/m2 + Carboplatin AUC 6 + Etoposide 100 mg/m201000
IMGN901 75 mg/m2 + Carboplatin AUC 5 + Etoposide 100 mg/m200000
IMGN901 75 mg/m2 + Carboplatin AUC 6 + Etoposide 100 mg/m211210
IMGN901 90 mg/m2 + Carboplatin AUC 5 + Etoposide 100 mg/m201100

[back to top]

Overview of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

To assess the type and frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs). An AE was defined as any noxious, pathologic, or unintended change un anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of the study, whether or not deemed study drug-related. An SAE was any AE resulting in death, life-threatening experience, initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, or congenital defect. All AEs were reported from the time of the first dose of study treatment until 28 days after the final dose of study drug. the severity of AEs were graded by the Investigator using National cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE) version 4.0. (NCT01237678)
Timeframe: From the first dose of study drug on Cycle 1, Day 1 until 28 days after the last study treatment (up to 22 months)

,,
Interventionparticipants (Number)
Any TEAERelated TEAEAny SAERelated SAETEAEs leading to discontinuationAny Grade ≥ 3 TEAERelated Grade ≥ 3 TEAEDeaths within 28 days of last dose
Phase I - IMGN901 + Carboplatin + Etoposide3332168829221
Phase II - Carboplatin + Etoposide4639239642335
Phase II - IMGN901 + Carboplatin + Etoposide9490543050928314

[back to top]

Overall Response Rate (ORR) of IMGN901 in Participants CD56 Expressing Hematological Malignancies

ORR, defined as CR (complete remission) + CRp (complete remission with incomplete platelet recovery) + CRi (complete remission with incomplete count recovery) within 3 cycles of therapy with IMGN901. (NCT02420873)
Timeframe: 53 days

InterventionParticipants (Count of Participants)
Cohort 1: CD56 Expressing Hematological Malignancies0
Cohort 2: Myelofibrosis0
Cohort 3: Blastic Plasmacytoid Dendritic Cell Neoplasm0

[back to top]

Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1

The best response of disease will be examined separately in each stratum. A responder is defined as a patient who achieves a best response of partial response or complete response on the study. Response rates will be calculated as the percent of evaluable patients who are responders, and Clopper-Pearson confidence intervals will be constructed. (NCT02452554)
Timeframe: Up to 18 weeks (6 courses)

InterventionPercent of participants (Number)
Stratum 1: Wims Tumor0.00
Stratum 2: Rhabdomyosarcoma6.25
Stratum 3: Neuroblastoma0.00
Stratum 4: Pleuropulmonary Blastoma0.00
Stratum 5: Malignant Peripheral Nerve Sheath Tumor0.00
Stratum 6: Synovial Sarcoma0.00

[back to top]

Incidence of Toxicities of Lorvotuzumab Mertansine, Using the NCI Common Terminology Criteria for Adverse Events Version 4.0

Toxicity tables will be constructed to summarize the observed incidence by type of toxicity and grade for toxicities with Possible, Probable, or Definite attribution to the study drug. Tables will summarize incidence by cycle. (NCT02452554)
Timeframe: Up to 12 months (17 courses)

InterventionTreatment cycles (Number)
Anemia: Grade 2Anemia: Grade 3Anemia: Grade 4Anemia: Grade 5Colonic fistula: Grade 2Colonic fistula: Grade 3Colonic fistula: Grade 4Colonic fistula: Grade 5Colonic perforation: Grade 2Colonic perforation: Grade 3Colonic perforation: Grade 4Colonic perforation: Grade 5Dental caries: Grade 2Dental caries: Grade 3Dental caries: Grade 4Dental caries: Grade 5Nausea: Grade 2Nausea: Grade 3Nausea: Grade 4Nausea: Grade 5Vomiting: Grade 2Vomiting: Grade 3Vomiting: Grade 4Vomiting: Grade 5Tooth infection: Grade 2Tooth infection: Grade 3Tooth infection: Grade 4Tooth infection: Grade 5Alanine aminotransferase increased: Grade 2Alanine aminotransferase increased: Grade 3Alanine aminotransferase increased: Grade 4Alanine aminotransferase increased: Grade 5Aspartate aminotransferase increased: Grade 2Aspartate aminotransferase increased: Grade 3Aspartate aminotransferase increased: Grade 4Aspartate aminotransferase increased: Grade 5Lymphocyte count decreased: Grade 2Lymphocyte count decreased: Grade 3Lymphocyte count decreased: Grade 4Lymphocyte count decreased: Grade 5Hyperglycemia: Grade 2Hyperglycemia: Grade 3Hyperglycemia: Grade 4Hyperglycemia: Grade 5Hyperuricemia: Grade 2Hyperuricemia: Grade 3Hyperuricemia: Grade 4Hyperuricemia: Grade 5Hypokalemia: Grade 2Hypokalemia: Grade 3Hypokalemia: Grade 4Hypokalemia: Grade 5Hypophosphatemia: Grade 2Hypophosphatemia: Grade 3Hypophosphatemia: Grade 4Hypophosphatemia: Grade 5Headache: Grade 2Headache: Grade 3Headache: Grade 4Headache: Grade 5Peripheral motor neuropathy: Grade 2Peripheral motor neuropathy: Grade 3Peripheral motor neuropathy: Grade 4Peripheral motor neuropathy: Grade 5Peripheral sensory neuropathy: Grade 2Peripheral sensory neuropathy: Grade 3Peripheral sensory neuropathy: Grade 4Peripheral sensory neuropathy: Grade 5All Reportable AEs: Grade 2All Reportable AEs: Grade 3All Reportable AEs: Grade 4All Reportable AEs: Grade 5
Treatment (Lorvotuzumab Mertansine)0200001000010100010011000100030001000200010001000100010010000100010021811

[back to top]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
maytansine
Maytansine: An ansa macrolide isolated from the MAYTENUS genus of East African shrubs.. maytansine : An organic heterotetracyclic compound and 19-membered macrocyclic lactam antibiotic originally isolated from the Ethiopian shrub Maytenus serrata but also found in other Maytenus species. It exhibits cytotoxicity against many tumour cell lines.		8.2293alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound		antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator
ConditionIndicatedRelationship StrengthStudiesTrials
Malignant Neurilemmoma
[description not available]		03.6411
Bilateral Wilms Tumor
[description not available]		05.1431
Synovioma
[description not available]		03.6411
Blastoma, Pulmonary
[description not available]		03.6411
Wilms Tumor
A malignant kidney tumor, caused by the uncontrolled multiplication of renal stem (blastemal), stromal (STROMAL CELLS), and epithelial (EPITHELIAL CELLS) elements. However, not all three are present in every case. Several genes or chromosomal areas have been associated with Wilms tumor which is usually found in childhood as a firm lump in a child's side or ABDOMEN.		010.1431
Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)		08.6411
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		08.6411
Sarcoma, Synovial
A malignant neoplasm arising from tenosynovial tissue of the joints and in synovial cells of tendons and bursae. The legs are the most common site, but the tumor can occur in the abdominal wall and other trunk muscles. There are two recognized types: the monophasic (characterized by sheaths of monotonous spindle cells) and the biphasic (characterized by slit-like spaces or clefts within the tumor, lined by cuboidal or tall columnar epithelial cells). These sarcomas occur most commonly in the second and fourth decades of life. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1363)		03.6411
Recrudescence
[description not available]		03.5911
Kahler Disease
[description not available]		04.8521
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		04.8521
Experimental Neoplasms
[description not available]		02.0810
Carcinoma, Small Cell Lung
[description not available]		03.0110
Carcinoma, Non-Small Cell Lung
[description not available]		03.0110
Granuloma, Hodgkin
[description not available]		03.0110
Cancer of Lung
[description not available]		03.0110
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		03.0110
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.0110
Hodgkin Disease
A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen.		03.0110
Lung Neoplasms
Tumors or cancer of the LUNG.		03.0110
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		03.0110
Small Cell Lung Carcinoma
A form of highly malignant lung cancer that is composed of small ovoid cells (SMALL CELL CARCINOMA).		03.0110
Benign Neoplasms
[description not available]		04.821
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		04.821
Cancer of Kidney
[description not available]		02.0810
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		02.0810